Kesara Na BangchangJuntra KarbwangDavid J. BackUniversity of LiverpoolMahidol University2018-08-102018-08-101992-05-08Biochemical Pharmacology. Vol.43, No.9 (1992), 1957-1961000629522-s2.0-0026510399https://repository.li.mahidol.ac.th/handle/20.500.14594/22255A number of drugs have been studied for their effect on the metabolism of the antimalarial drug mefloquine by human liver microsomes (N = 6) in vitro. The only metabolite generated was identified as carboxymefloquine by co-chromatography with the authentic standard. Ketoconazole caused marked inhibition of carboxymefloquine formation with ic50and Kivalues of 7.5 and 11.2 μM, respectively. The inhibition by ketoconazole, a known inhibitor of cytochrome P450 isozymes, and the dependency of metabolite formation on the presence of NADPH indicated that cytochrome P450 isozyme(s) catalysed metabolite production. Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (ic50, 17.5 and 122 μM; Ki, 8.6 and 28.5 μM, respectively). However, despite these in vitro data with primaquine, clinical studies have failed to show any significant effect of single dose primaquine on the pharmacokinetics of mefloquine. With quinine, because peak plasma concentrations are very close to the Kivalue, there is likely to be inhibition of mefloquine metabolism in patients receiving both drugs. Sulfadoxine, artemether, artesunate and tetracycline did not significantly inhibit carboxymefloquine formation. © 1992.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyPharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1016/0006-2952(92)90638-Y